linezolid

linezolid is a synthetic antibacterial agent belonging to the oxazolidinone class of medications. It is primarily used to treat infections caused by Gram-positive bacteria, including those resistant to other antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Developed by Pharmacia & Upjohn, it received approval from the U.S. Food and Drug Administration in 2000, representing the first new class of antibiotics introduced in decades.

Medical uses

linezolid is indicated for the treatment of complicated skin and skin structure infections, community-acquired pneumonia, and hospital-acquired pneumonia caused by susceptible organisms like Staphylococcus aureus and Streptococcus pneumoniae. It is also used for infections due to vancomycin-resistant Enterococcus faecium, including cases of bacteremia. The World Health Organization includes it on its Model List of Essential Medicines, and it is often reserved for serious infections where other options have failed or are not suitable, following guidelines from institutions like the Infectious Diseases Society of America.

Adverse effects

Common adverse effects include headache, nausea, diarrhea, and vomiting. A significant concern is the potential for myelosuppression, particularly thrombocytopenia and anemia, which is often dose- and duration-dependent and requires monitoring of complete blood count. linezolid use has been associated with peripheral neuropathy and optic neuritis, especially with prolonged courses exceeding 28 days. Another serious, though rare, adverse effect is serotonin syndrome, particularly when co-administered with serotonergic drugs such as selective serotonin reuptake inhibitors.

Mechanism of action

linezolid exerts its bacteriostatic activity against most susceptible organisms by inhibiting protein synthesis. It binds to the 50S ribosomal subunit of the bacterial ribosome, specifically at the P site, and prevents the formation of the functional initiation complex required for translation. This action blocks the interaction between fMet-tRNA and the ribosome, halting the early stage of peptide bond formation. Unlike other classes of protein synthesis inhibitors such as macrolides or chloramphenicol, its unique binding site minimizes cross-resistance.

Pharmacokinetics

linezolid demonstrates excellent bioavailability after oral administration, approaching 100%, allowing for seamless transition from intravenous therapy to oral dosing. It is widely distributed throughout the body, achieving good penetration into tissues such as skin, lungs, and cerebrospinal fluid. Metabolism occurs primarily in the liver via non-enzymatic, oxidative processes not involving the CYP450 system. Elimination occurs via both renal and non-renal routes, with approximately 30-35% excreted unchanged in the urine and about 50-55% appearing as inactive metabolites in the feces.

History and society

The development of linezolid was spearheaded by researchers at Pharmacia & Upjohn in the 1990s. Its approval by the U.S. Food and Drug Administration in April 2000 marked a significant milestone as the first oxazolidinone antibiotic commercialized. The drug was subsequently granted orphan drug status for certain indications and its patent expiration in various markets has led to the introduction of generic versions. Its role in combating antimicrobial resistance has been highlighted in reports by the Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control.

Resistance

Although initially effective against resistant strains, reports of linezolid resistance have emerged globally, mediated by mechanisms such as mutations in the 23S ribosomal RNA gene and the acquisition of the cfr gene, which encodes a methyltransferase that modifies the antibiotic's binding site. The presence of the optrA and poxtA genes, which facilitate efflux and ribosomal protection, has also been documented in isolates from locations like the United States and China. Surveillance programs, including those by The European Committee on Antimicrobial Susceptibility Testing (EUCAST), monitor its minimum inhibitory concentration breakpoints to guide clinical use.